Positive data for Amylyx’s AMX0035 strengthen its position to enter ALS market

On October 16, Amylyx announced that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed...

Trials disrupted due to Covid-19 continue to resume

Positive vote from FDA’s Advisory Committee for Alkermes’ ALKS-3831 strengthens its potential position in the Schizophrenia market

On the 9th of October, Alkermes announced positive voting from the joint meeting of the...

Covid-19 Vaccine Development Across the Globe

With the persisting global devastation of COVID-19, researchers worldwide are moving at a rapid pace...

AstraZeneca’s quick Covid-19 vaccine trial restart splits experts

Eli Lilly’s and Regeneron’s EUA talk trigger prudence on available Covid-19 data

Kala’s dry eye syndrome steroid likely to be FDA approved; mixed potential on uptake

Overall clinical trial disruption due to Covid-19 declines, but the number of trials with slow recruitment continues to grow

Since early March, around 1,000 organizations supporting clinical trials as a sponsor, collaborator, or contract...

New frontiers in the treatment of metastatic urothelial carcinoma raises hopes for patients and their families

vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains